|
Ariad Pharmaceuticals Incorporated - Company Profile Snapshot
| Company Profile: |
Ariad Pharmaceuticals Incorporated |
| Ticker: |
ARIA |
| Exchanges: |
NAS |
| 2008 Sales: |
7,082,000 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
UNITED STATES |
| Employees: |
150 |
Business Description
Ariad Pharmaceuticals Incorporated. The Group's principal activities are the discovery and development of medicines that treat cancer by regulating cell signaling with small molecules. The Group's lead product candidate, AP23573, is in multiple Phase 1 and Phase 2 clinical trials and is used for the treatment of solid tumors and hematologic cancers. In the Group's bone-targeted mTOR inhibitor program, it is developing a novel and potent follow-on product candidate analogous to AP23573, which treats bone cancers and block the spread of bone sarcomas. In the Group's oncogenic kinase inhibitor program, it is developing potent inhibitors of enzymes involved in the growth, proliferation and spread of cancer. The Group operates in the United States.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
